Under the terms of the settlement agreement, the litigation, which was pending before the US District Court of California, has now been fully resolved and dismissed.
The settlement resolves disputed issues with respect to MedImmune’s marketed product Synagis (palivizumab) as well as a related product (motavizumab) for which MedImmune is seeking regulatory approval.
The settlement also permits MedImmune to obtain licenses for certain additional pipeline products under the Cabilly patent family.